



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_35710
Title of the Manuscript:	Evaluation of Efficacy of Gefinitib in Comparison with Chemotherapy in Patients with Non-Small Cell Lung Carcinoma from India.
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	In "Abstract" in "Methods" chapter the following information should be given: "28 patients positive for EGFR mutations and 18 patients negative for EGFR were enrolled into the study" There is no information WHEN the study was conducted. Line 148-149: it should be deleted as it is the aim of the study. Line 149-155: it should be deleted as it is NOT DISCUSSION, but general information.	All the comments have now been incorporated. We thank the reviewer.
Minor REVISION comments	As many as 19 References are out-of dated (i.e. over 10 year old): -No 3 comes from 1990 -No 4 and No 6 and No 9 and No 10 and No 22 and No 23 come from 2001 -No 7 comes from 1993 -No 8 comes from 1998 -No 11 and No 14 and No 21 come from 2002 -No 13 and No 15 and No 16 come from 2003 -No 19 comes from 2000 -No 20 comes from 1996 -No 32 and No 33 come from 2005 I would advise to delete these old-fashioned publications.	Some of the older references have now been deleted. These include No. 19, 20, 21, 22,23.
Optional/General comments	The main disadvantage of the study is a very limited study group (only 46 patients).	This point is already mentioned in the last paragraph of the paper.